Loading..

ADMA Biologics, Inc. (ADMA) Report Analysis

Corporate Events

Negative

ADMA Biologics, Inc. Receives FDA Approval for ...

2022-06-27 20:31:00

ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration approval for its sixth ADMA BioCenters plasma collection...

Positive

ADMA Biologics BioCenters Receives FDA Approval...

2022-06-27 11:00:00

ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration ("FDA") approval for its sixth ADMA BioCenters plasma co...

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000 Growth Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Value Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Growth Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell Small Cap Comp Growth Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000 Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000 Value Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell Small Cap Completeness Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2500 Value Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2500 Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell Small Cap Comp Value Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Dynamic Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000E Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000E Value Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000E Growth Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Ru...

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2500 Growth Index

Neutral

ADMA Biologics, Inc. Provides Revenue Guidance ...

2022-05-11 20:16:00

ADMA Biologics, Inc. provided revenue guidance for the remainder of 2022. Over the remainder of 2022, the company expects to deliver significa...

Positive

ADMA Biologics, Inc. Revises Earnings Guidance ...

2022-05-11 20:05:00

ADMA Biologics, Inc. revised earnings guidance for the year 2022. ADMA increases 2022 total revenue guidance to $130 million or more, upwardly...

Neutral

ADMA Biologics, Inc. to Report Q1, 2022 Results...

2022-05-04 11:00:00

ADMA Biologics, Inc. announced that they will report Q1, 2022 results After-Market on May 11, 2022

Neutral

ADMA Biologics, Inc., Q1 2022 Earnings Call, Ma...

2022-05-04 11:00:00

ADMA Biologics, Inc., Q1 2022 Earnings Call, May 11, 2022

Neutral

ADMA Biologics, Inc., Annual General Meeting, J...

2022-04-28 20:36:00

ADMA Biologics, Inc., Annual General Meeting, Jun 21, 2022, at 10:00 US Eastern Standard Time. Agenda: To consider a proposal to elect two cla...

Neutral

ADMA Biologics, Inc. - Shareholder/Analyst Call

2022-04-28 20:36:00

AGM

Neutral

ADMA Biologics, Inc., ASCENIV™ Reduces Viral In...

2022-04-01 11:00:00

ADMA Biologics, Inc., ASCENIV™ Reduces Viral Infections, Apr 01, 2022. Venue: Exhibit Hall, Symphony Ballroom, Sheraton Charlotte Hotel, 55 So...

Neutral

ADMA Biologics, Inc. Presents at Clinical Immun...

2022-04-01 08:54:00

ADMA Biologics, Inc. Presents at Clinical Immunology Society 2022 Annual Meeting Conference, Mar-28-2022 . Venue: Charlotte, North Carolina, U...

Neutral

Clinical Immunology Society, Clinical Immunolog...

2022-03-28 02:32:00

Clinical Immunology Society, Clinical Immunology Society 2022 Annual Meeting Conference, Mar 28, 2022. Venue: Charlotte, North Carolina, Unite...

Neutral

ADMA Biologics, Inc., Board Meeting, Dec 14, 2021

2021-12-21 21:49:00

ADMA Biologics, Inc., Board Meeting, Dec 14, 2021. Agenda: To adopt the resolution with respect to the designations, number of shares, prefere...

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to NA...

2021-12-20 00:00:00

ADMA Biologics, Inc. has been added to NASDAQ Biotechnology Index.

Neutral

ADMA Biologics, Inc. Presents at BioFlorida Con...

2021-12-07 04:14:00

ADMA Biologics, Inc. Presents at BioFlorida Conference, Dec-10-2021 08:30 AM. Venue: Renaissance Orlando at SeaWorld, 6677 Sea Harbor Dr, Orla...

Positive

ADMA Biologics, Inc. Advances Plasma Collection...

2021-11-16 12:00:00

ADMA Biologics, Inc. announced the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters locatio...

Neutral

ADMA Biologics, Inc. to Report Q3, 2021 Results...

2021-11-03 11:00:00

ADMA Biologics, Inc. announced that they will report Q3, 2021 results After-Market on Nov 10, 2021

Neutral

ADMA Biologics, Inc., Q3 2021 Earnings Call, No...

2021-11-03 11:00:00

ADMA Biologics, Inc., Q3 2021 Earnings Call, Nov 10, 2021

Negative

ADMA Biologics, Inc. has completed a Follow-on ...

2021-10-21 00:00:00

ADMA Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million. Security Name: Common Stock Security Type: Co...

Negative

ADMA Biologics, Inc. has filed a Follow-on Equi...

2021-10-20 00:00:00

ADMA Biologics, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock

Positive

ADMA Biologics Evaluates Variety of Strategic a...

2021-10-20 00:00:00

ADMA Biologics, Inc. (NasdaqGM:ADMA) is currently evaluating a variety of strategic and financing alternatives and have engaged Morgan Stanley...

Neutral

ADMA Biologics, Inc. Presents at ISIRV-WHO Virt...

2021-10-19 08:38:00

ADMA Biologics, Inc. Presents at ISIRV-WHO Virtual Conference-COVID-19, Oct-19-2021 .

Negative

ADMA Biologics, Inc. Announces the Appointment ...

2021-10-18 11:00:00

ADMA Biologics, Inc. announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate...

Neutral

ADMA Biologics, Inc. Presents at IDWeek, Sep-29-2021

2021-10-04 11:00:00

ADMA Biologics, Inc. Presents at IDWeek, Sep-29-2021 .

Neutral

BioFlorida, Inc., Brain Foundation, BioFlorida ...

2021-10-01 16:14:00

BioFlorida, Inc., Brain Foundation, BioFlorida Conference, Dec 08, 2021 through Dec 10, 2021. Venue: Renaissance Orlando at SeaWorld, 6677 Sea...

Neutral

ADMA Biologics, Inc. - Special Call

2021-10-01 11:00:00

Key Insights on RSV and Other Respiratory Viruses Beyond COVID-19 in the Immunocompromised: An Expert Discussion

Neutral

International Society For Influenza And Other R...

2021-09-27 11:20:00

International Society For Influenza And Other Respiratory Virus Diseases, World Health Organization, ISIRV-WHO Virtual Conference-COVID-19, Oc...

Neutral

ADMA Biologics, Inc. Presents at Cantor Global ...

2021-09-23 11:00:00

ADMA Biologics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 09:20 AM. Venue: New York, United States. Speakers: Ada...

Neutral

Infectious Diseases Society of America, IDWeek,...

2021-09-16 09:57:00

Infectious Diseases Society of America, IDWeek, Sep 29, 2021 through Oct 03, 2021.

Positive

ADMA Biologics, Inc. Receives FDA Approval for ...

2021-09-08 11:00:00

ADMA Biologics, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has granted approval for the company’s in-house aseptic fill...

Neutral

ADMA Biologics, Inc. Presents at Morgan Stanley...

2021-09-07 09:02:00

ADMA Biologics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-09-2021 12:30 PM. Venue: New Windsor, United Sta...

Negative

ADMA Biologics, Inc. has filed a Follow-on Equi...

2021-09-03 00:00:00

ADMA Biologics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Security Name: Common Stock Security Type: Common...

Neutral

ADMA Biologics, Inc. Presents at PDA Pharmaceut...

2021-08-27 11:21:00

ADMA Biologics, Inc. Presents at PDA Pharmaceutical Microbiology Conference, Oct-04-2021 . Venue: Washigton, District Of Columbia, United Stat...

Neutral

Parenteral Drug Association, PDA Pharmaceutical...

2021-08-27 10:55:00

Parenteral Drug Association, PDA Pharmaceutical Microbiology Conference, Oct 04, 2021 through Oct 06, 2021. Venue: Washigton, District Of Colu...

Positive

ADMA Biologics Receives FDA Approval for ADMA B...

2021-08-16 21:16:00

ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration approval for its ADMA BioCenters plasma collection facil...

Positive

ADMA Biologics, Inc. Advances Expansion Plans a...

2021-08-10 20:30:00

ADMA Biologics, Inc. announced the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters plasma ...

Positive

ADMA Biologics, Inc Announces Commercial Availa...

2021-08-09 11:00:00

ADMA Biologics, Inc. announced the commercial availability of additional vial sizes of BIVIGAM and NABI-HB, which are currently in stock and c...

Neutral

ADMA Biologics, Inc., Q2 2021 Earnings Call, Au...

2021-08-04 11:00:00

ADMA Biologics, Inc., Q2 2021 Earnings Call, Aug 11, 2021

Neutral

ADMA Biologics, Inc. to Report Q2, 2021 Results...

2021-08-04 11:00:00

ADMA Biologics, Inc. announced that they will report Q2, 2021 results After-Market on Aug 11, 2021

Negative

ADMA Biologics, Inc. Announces Successful Compl...

2021-07-20 11:00:00

ADMA Biologics, Inc. announced the United States Food and Drug Administration recently completed a Pre-Approval Inspection of the Boca Raton, ...

Negative

ADMA Biologics, Inc. Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC

2022-06-27 20:31:00

ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration approval for its sixth ADMA BioCenters plasma collection facility located in Myrtle Beach, South Carolina. This plasma collection facility commenced operations and initiated source plasma collection in the fourth quarter of 2021. With the approval announced on June 27, 2022, this facility is now FDA-approved to collect and introduce into interstate commerce, human source plasma for further manufacturing in the U.S. This new plasma collection center features automated registration, high-tech collection equipment designed to shorten the donation process, free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable at each donor station, and highly trained and certified staff who put donor comfort and safety first. At full capacity, the plasma center expects to maintain a staff of 50 highly trained healthcare workers. This center is approved to use the Haemonetics NexSys Persona® plasma collection system.

Positive

ADMA Biologics BioCenters Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC

2022-06-27 11:00:00

ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration ("FDA") approval for its sixth ADMA BioCenters plasma collection facility located in Myrtle Beach, South Carolina. This plasma collection facility commenced operations and initiated source plasma collection in the fourth quarter of 2021. With the approval announced, this facility is now FDA-approved to collect and introduce into interstate commerce, human source plasma for further manufacturing in the U.S. This new, state-of-the-art plasma collection center features automated registration, high-tech collection equipment designed to shorten the donation process, free Wi-Fi wireless network in the donor collection area, individual flat- screen TVs with cable at each donor station, and highly trained and certified staff who put donor comfort and safety first. At full capacity, the plasma center expects to maintain a staff of 50 highly trained healthcare workers. This center is approved to use the state-of-the-art Haemonetics NexSys Persona(R) plasma collection system.

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000 Growth Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000 Growth Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Value Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Value Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Growth Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Growth Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell Small Cap Comp Growth Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell Small Cap Comp Growth Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000 Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000 Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000 Value Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000 Value Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell Small Cap Completeness Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell Small Cap Completeness Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2500 Value Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2500 Value Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2500 Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2500 Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell Small Cap Comp Value Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell Small Cap Comp Value Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Dynamic Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Dynamic Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000E Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000E Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000E Value Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000E Value Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000E Growth Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 3000E Growth Index

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2500 Growth Index

2022-06-24 00:00:00

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2500 Growth Index

Neutral

ADMA Biologics, Inc. Provides Revenue Guidance for the Remainder of 2022

2022-05-11 20:16:00

ADMA Biologics, Inc. provided revenue guidance for the remainder of 2022. Over the remainder of 2022, the company expects to deliver significant revenue growth and market share gains for the company's product portfolio, improve margins as operating leverage is realized, and continue to prioritize the exploration of strategic alternatives, to maximize stockholder value.

Positive

ADMA Biologics, Inc. Revises Earnings Guidance for the Year 2022

2022-05-11 20:05:00

ADMA Biologics, Inc. revised earnings guidance for the year 2022. ADMA increases 2022 total revenue guidance to $130 million or more, upwardly revised from $125 million. ADMA reiterates expectations to grow revenues and gross profits and narrow net losses as 2022 progresses.

Neutral

ADMA Biologics, Inc. to Report Q1, 2022 Results on May 11, 2022

2022-05-04 11:00:00

ADMA Biologics, Inc. announced that they will report Q1, 2022 results After-Market on May 11, 2022

Neutral

ADMA Biologics, Inc., Q1 2022 Earnings Call, May 11, 2022

2022-05-04 11:00:00

ADMA Biologics, Inc., Q1 2022 Earnings Call, May 11, 2022

Neutral

ADMA Biologics, Inc., Annual General Meeting, Jun 21, 2022

2022-04-28 20:36:00

ADMA Biologics, Inc., Annual General Meeting, Jun 21, 2022, at 10:00 US Eastern Standard Time. Agenda: To consider a proposal to elect two class iii directors to serve on the company’s board of directors for a term expiring at the 2025 annual meeting of stockholders and until their successors are duly elected and qualified, or until such director’s earlier resignation, removal or death; to consider a proposal to approve the adma biologics, inc. 2022 equity compensation plan; to consider a proposal to approve the compensation of the company’s named executive officers, on an advisory basis; and to consider other matters.

Neutral

ADMA Biologics, Inc. - Shareholder/Analyst Call

2022-04-28 20:36:00

AGM

Neutral

ADMA Biologics, Inc., ASCENIV™ Reduces Viral Infections, Apr 01, 2022

2022-04-01 11:00:00

ADMA Biologics, Inc., ASCENIV™ Reduces Viral Infections, Apr 01, 2022. Venue: Exhibit Hall, Symphony Ballroom, Sheraton Charlotte Hotel, 55 South McDowell Street South Tower, Charlotte, NC, New Jersey, New Jersey, United States. Poster Presentation Title: ASCENIV™ Reduces Viral Infections and Associated Comorbidities in a Primary Immunodeficiency PatientSession Date: Friday, April 1, 2022Session Time: 1:00 PM – 2:00 PM ETSession Location: Exhibit Hall, Symphony Ballroom, Sheraton Charlotte Hotel, 55 South McDowell Street South Tower, Charlotte, NCPoster Presentation and Abstract Number: #47.

Neutral

ADMA Biologics, Inc. Presents at Clinical Immunology Society 2022 Annual Meeting Conference, Mar-28-2022

2022-04-01 08:54:00

ADMA Biologics, Inc. Presents at Clinical Immunology Society 2022 Annual Meeting Conference, Mar-28-2022 . Venue: Charlotte, North Carolina, United States.

Neutral

Clinical Immunology Society, Clinical Immunology Society 2022 Annual Meeting Conference, Mar 28, 2022

2022-03-28 02:32:00

Clinical Immunology Society, Clinical Immunology Society 2022 Annual Meeting Conference, Mar 28, 2022. Venue: Charlotte, North Carolina, United States.

Neutral

ADMA Biologics, Inc., Board Meeting, Dec 14, 2021

2021-12-21 21:49:00

ADMA Biologics, Inc., Board Meeting, Dec 14, 2021. Agenda: To adopt the resolution with respect to the designations, number of shares, preferences, voting powers and other rights and the restrictions and limitations thereof, of the Series A Junior Participating Preferred Stock.

Positive

ADMA Biologics, Inc.(NasdaqGM:ADMA) added to NASDAQ Biotechnology Index

2021-12-20 00:00:00

ADMA Biologics, Inc. has been added to NASDAQ Biotechnology Index.

Neutral

ADMA Biologics, Inc. Presents at BioFlorida Conference, Dec-10-2021 08:30 AM

2021-12-07 04:14:00

ADMA Biologics, Inc. Presents at BioFlorida Conference, Dec-10-2021 08:30 AM. Venue: Renaissance Orlando at SeaWorld, 6677 Sea Harbor Dr, Orlando, Florida, United States. Speakers: Adam S. Grossman, Co-Founder, President, CEO & Director.

Positive

ADMA Biologics, Inc. Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC

2021-11-16 12:00:00

ADMA Biologics, Inc. announced the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters location in Myrtle Beach, South Carolina. ADMA BioCenters’ newest, plasma collection center located in Myrtle Beach, South Carolina features automated registration, Haemonetics’ Persona plasma collection solution for the NexSys PCS system designed to shorten the donation process and increase collection yields, free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable at each donor station, and highly trained and certified staff who put donor comfort and safety first. At full capacity, the center expects to maintain a staff of up to 50 highly trained healthcare workers. Pursuant to updated FDA direction to obtain approval for plasma collection centers, sponsors are now required to collect plasma donations for three months prior to submitting a Biologics License Application filing. Accordingly, ADMA expects to file its BLA for the Myrtle Beach, South Carolina plasma collection facility in approximately three months and anticipates a standard 12-month BLA review period by the FDA. In the meantime, ADMA is permitted to collect plasma donations at this site and, once the site is FDA approved, ADMA can utilize the plasma collected for further use in the manufacturing of life saving therapies.

Neutral

ADMA Biologics, Inc. to Report Q3, 2021 Results on Nov 10, 2021

2021-11-03 11:00:00

ADMA Biologics, Inc. announced that they will report Q3, 2021 results After-Market on Nov 10, 2021

Neutral

ADMA Biologics, Inc., Q3 2021 Earnings Call, Nov 10, 2021

2021-11-03 11:00:00

ADMA Biologics, Inc., Q3 2021 Earnings Call, Nov 10, 2021

Negative

ADMA Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

2021-10-21 00:00:00

ADMA Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: $1 Discount Per Security: $0.06

Negative

ADMA Biologics, Inc. has filed a Follow-on Equity Offering.

2021-10-20 00:00:00

ADMA Biologics, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock

Positive

ADMA Biologics Evaluates Variety of Strategic and Financing Alternatives

2021-10-20 00:00:00

ADMA Biologics, Inc. (NasdaqGM:ADMA) is currently evaluating a variety of strategic and financing alternatives and have engaged Morgan Stanley (NYSE:MS) as a financial advisor in connection with certain of those strategic alternatives.

Neutral

ADMA Biologics, Inc. Presents at ISIRV-WHO Virtual Conference-COVID-19, Oct-19-2021

2021-10-19 08:38:00

ADMA Biologics, Inc. Presents at ISIRV-WHO Virtual Conference-COVID-19, Oct-19-2021 .

Negative

ADMA Biologics, Inc. Announces the Appointment of Young T. Kwon, Ph.D., to Its Board of Directors

2021-10-18 11:00:00

ADMA Biologics, Inc. announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in strategic advising, corporate finance and business development transactions to ADMA’s Board.

Neutral

ADMA Biologics, Inc. Presents at IDWeek, Sep-29-2021

2021-10-04 11:00:00

ADMA Biologics, Inc. Presents at IDWeek, Sep-29-2021 .

Neutral

BioFlorida, Inc., Brain Foundation, BioFlorida Conference, Dec 08, 2021 through Dec 10, 2021

2021-10-01 16:14:00

BioFlorida, Inc., Brain Foundation, BioFlorida Conference, Dec 08, 2021 through Dec 10, 2021. Venue: Renaissance Orlando at SeaWorld, 6677 Sea Harbor Dr, Orlando, Florida, United States.

Neutral

ADMA Biologics, Inc. - Special Call

2021-10-01 11:00:00

Key Insights on RSV and Other Respiratory Viruses Beyond COVID-19 in the Immunocompromised: An Expert Discussion

Neutral

International Society For Influenza And Other Respiratory Virus Diseases, World Health Organization, ISIRV-WHO Virtual Conference-COVID-19, Oct 19, 2021 through Oct 21, 2021

2021-09-27 11:20:00

International Society For Influenza And Other Respiratory Virus Diseases, World Health Organization, ISIRV-WHO Virtual Conference-COVID-19, Oct 19, 2021 through Oct 21, 2021.

Neutral

ADMA Biologics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 09:20 AM

2021-09-23 11:00:00

ADMA Biologics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 09:20 AM. Venue: New York, United States. Speakers: Adam S. Grossman, Co-Founder, President, CEO & Director.

Neutral

Infectious Diseases Society of America, IDWeek, Sep 29, 2021 through Oct 03, 2021

2021-09-16 09:57:00

Infectious Diseases Society of America, IDWeek, Sep 29, 2021 through Oct 03, 2021.

Positive

ADMA Biologics, Inc. Receives FDA Approval for VanRx Aseptic Fill-Finish Machine and Related Operations

2021-09-08 11:00:00

ADMA Biologics, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has granted approval for the company’s in-house aseptic fill-finish machine, the VanRx SA25 (“VanRx”). The VanRx fill-finish machine utilizes a closed isolator design, allowing for the removal of human interventions and providing safe drug products for patients. The VanRx machine has the capability of rapidly switching between different container and closure formats, enabling aseptic filling in a variety of different fill volumes and presentation sizes. The combination of the FDA-approved increased BIVIGAM® manufacturing production scale earlier this year as well as the enhanced vertical integration resulting from this approval of the VanRx machine is expected to allow ADMA to bring its products to market faster, improve gross margins and substantially increase ADMA’s end-to-end control over its critical manufacturing process. ADMA will continue to work with its third-party contract manufacturing organization (CMO) fill-finish partner who will continue to fill a portion of ADMA’s production at their site. The CMO’s site will remain in ADMA’s FDA-approved product Biologics License Applications to provide the Company with alternatives on a go-forward basis to ensure continued supply-chain robustness.

Neutral

ADMA Biologics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-09-2021 12:30 PM

2021-09-07 09:02:00

ADMA Biologics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-09-2021 12:30 PM. Venue: New Windsor, United States. Speakers: Adam S. Grossman, Co-Founder, President, CEO & Director.

Negative

ADMA Biologics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

2021-09-03 00:00:00

ADMA Biologics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering

Neutral

ADMA Biologics, Inc. Presents at PDA Pharmaceutical Microbiology Conference, Oct-04-2021

2021-08-27 11:21:00

ADMA Biologics, Inc. Presents at PDA Pharmaceutical Microbiology Conference, Oct-04-2021 . Venue: Washigton, District Of Columbia, United States. Speakers: Joseph E. McCall, Director of Quality Assurance Technical Services.

Neutral

Parenteral Drug Association, PDA Pharmaceutical Microbiology Conference, Oct 04, 2021 through Oct 06, 2021

2021-08-27 10:55:00

Parenteral Drug Association, PDA Pharmaceutical Microbiology Conference, Oct 04, 2021 through Oct 06, 2021. Venue: Washigton, District Of Columbia, United States.

Positive

ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN

2021-08-16 21:16:00

ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration approval for its ADMA BioCenters plasma collection facility located in Maryville, Tennessee. This plasma collection facility commenced operations and initiated source plasma collection in the fourth quarter of 2020. With today’s approval, this facility is now FDA-licensed to collect and introduce into interstate commerce human source plasma for further manufacturing in the U.S. This new plasma collection center features automated registration, high-tech collection equipment designed to shorten the donation process, free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable at each donor station, and highly trained and certified staff who put donor comfort and safety first. At full capacity, the plasma center expects to maintain a staff of 50 highly trained healthcare workers. This center is approved to use the Haemonetics NexSys Persona® plasma collection system.

Positive

ADMA Biologics, Inc. Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System

2021-08-10 20:30:00

ADMA Biologics, Inc. announced the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters plasma collection facility located in Conyers, Georgia. In conjunction with the plasma collection center opening, ADMA also announced the implementation of the Haemonetics’ Persona® Plasma Collection Solution for the NexSys PCS® system (Persona) across its plasma collection center network. ADMA BioCenters’ newest, state-of-the-art plasma collection center located in Conyers, Georgia features automated registration, high-tech collection equipment designed to shorten the donation process, free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable at each donor station, and highly trained and certified staff who put donor comfort and safety first. At full capacity, the center expects to maintain a staff of up to 50 highly trained healthcare workers. Pursuant to updated United States Food and Drug Administration (“FDA”) guidance to obtain approval for plasma collection centers, sponsors are now required to collect plasma donations for three months prior to submitting a Biologics License Application (“BLA”) filing. Accordingly, ADMA expects to file its BLA for the Conyers, Georgia plasma collection facility in approximately three months and anticipates a standard 12-month BLA review period by the FDA. In the meantime, ADMA is permitted to collect plasma donations at this site and, once the site is FDA approved, ADMA can utilize the plasma collected for further use in the manufacturing of life saving therapies. New plasma donors can receive $70 on the first donation and up to $650/month.

Positive

ADMA Biologics, Inc Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB®

2021-08-09 11:00:00

ADMA Biologics, Inc. announced the commercial availability of additional vial sizes of BIVIGAM and NABI-HB, which are currently in stock and commercially available to U.S healthcare providers and patients. NABI-HB 1 mL and 5 mL vial sizes are available to U.S. healthcare providers and patients and, at the present time, ADMA expects continuous supply availability of both vial sizes going forward.

Neutral

ADMA Biologics, Inc., Q2 2021 Earnings Call, Aug 11, 2021

2021-08-04 11:00:00

ADMA Biologics, Inc., Q2 2021 Earnings Call, Aug 11, 2021

Neutral

ADMA Biologics, Inc. to Report Q2, 2021 Results on Aug 11, 2021

2021-08-04 11:00:00

ADMA Biologics, Inc. announced that they will report Q2, 2021 results After-Market on Aug 11, 2021

Negative

ADMA Biologics, Inc. Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection

2021-07-20 11:00:00

ADMA Biologics, Inc. announced the United States Food and Drug Administration recently completed a Pre-Approval Inspection of the Boca Raton, FL manufacturing facility related to ADMA's application for its VanRx SA25 Workcell aseptic fill-finish machine. The PAI successfully concluded with the FDA issuing zero Form 483 observations in the Agency’s determination that the Company’s Boca Raton, FL facility continues to operate in compliance with the principles and guidelines of Good Manufacturing Practices standards. The FDA’s review of ADMA’s VanRx regulatory filing remains ongoing, with anticipated regulatory approval in the second half of 2021. The VanRx fill-finish machine utilizes a state-of-the-art closed isolator design, allowing for the removal of human interventions and providing safe drug products for patients. The VanRx machine has the capability of rapidly switching between different container and closure formats, enabling aseptic filling in a variety of different fill volumes and presentation sizes. The combination of the recently FDA-approved increased BIVIGAM® manufacturing production scale as well as the enhanced vertical integration that will result from the anticipated approval of the VanRx machine will allow ADMA to bring its products to market faster, improve gross margins and substantially increase ADMA’s end-to-end control over its critical manufacturing process.

Fundamental Summary

ADMA Biologics's recently released results from Q1 indicate that ADMA Biologics is performing reasonably well and on par with its peers. The company's growth, value, and income factors all individually appear positive and give support for optimism regarding the likelihood of continued positive performance. We gave ADMA Biologics a 64 rating and a HOLD recommendation.

ADMA Biologics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 29.1 million compared to USD 16.05 million a year ago. Net loss was USD 25.01 million compared to USD 18.38 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.16 a year ago.

Business Description

ADMA Biologics, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Sector Overview

ADMA Biologics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. ADMA Biologics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 308.0 11.5% 68
Liabilities 181.1 34.1% 74
Price to Book 3.3 70.8% 72
Cash & Equivalents 69.5 36.0% 77
Equity 126.9 -10.1% 49
EBITDA -49.9 1.6% 65
Total Revenues 94.0 16.1% 43
Parameter Value Change Score
Return on Equity -65.4 -4.7% 62
Net Cashflow 7.5 256.0% 62
Capital Expenditure -13.8 -2.0% 74
Asset Turnover 0.3 3.4% 85
Free Cashflow -0.7 17.4% 77

* All values are TTM

The below chart reflects ADMA Biologics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While ADMA Biologics's peer average final assessment score stands on 64.0, ADMA Biologics's score is 64.

  •  ADMA
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 7 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 8 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 9 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 10 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 11 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 12 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 13 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 14 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 15 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 16 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 17 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 18 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. ADMA Biologics's stock is now priced above its 50-day and 200-day, but below its 5-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), ADMA Biologics's stock indicates that it's likely oversold. Overall, these technical indicators signal positive upward momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 73.

Bullish 73
Close Price 2.02
52W Low 1.09
52W High 2.2
5D MA 2.07
50D MA 1.96
200D MA 1.58
MACD 0.04
RSI 8.46
STOCH 40.0

Balance Sheet Analysis

Cash & Equivalents and Liabilities stood out as the most significant drivers of ADMA Biologics's balance sheet strength. ADMA Biologics's management was effective in improving its cash and cash equivalents metrics, which now sit at 69.5. This represents 36.0% change from the last reporting period. Its impressive cash and cash equivalents metrics should support upward pressure on its's stock price. The company's cash and cash equivalents movement, therefore, received a grade of 77. Also, ADMA Biologics is doing a good job of keeping its liabilities under control and growing intelligently. At filing, their liabilities were 181.1, representing 34.1% change from the previous period. These numbers show that management has successfully encouraged growth while managing liabilities, especially relative to their peers. The company's liabilities movement component, therefore, received a grade of 74. However, one concerning metric, Equity, stood out. ADMA Biologics published concerning equity metrics for this filing. In the current report, equity stood at 126.9, which represents a -10.1% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. Their equity metrics appear unremarkable relative to their peers. Therefore, their equity movement component earned a score of 49. The company's balance sheet, Therefore, earned a score of 68.

Parameter Value Change Score
Assets 308.0 11.5% 68
Liabilities 181.1 34.1% 74
Price to Book 3.3 70.8% 72
Cash & Equivalents 69.5 36.0% 77
Equity 126.9 -10.1% 49
* All values are TTM

The below chart describes ADMA Biologics's performance as reflected on its balance sheet with respect to its peers. While ADMA Biologics received a balance sheet score of 68, the average of its peers stands on 66.0.

  •  ADMA
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 7 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 8 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 9 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 10 1
CareDx, Inc 1.2B 54 67 52 39 51 52 11 1
MannKind Corporation 957.2M 79 59 50 40 64 57 12 1
Merus N.V. 941.6M 59 68 50 83 81 70 13 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 15 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 16 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 17 1
Affimed N.V. 415.0M 56 66 63 56 47 54 18 1
AC Immune SA 299.8M 84 64 47 53 75 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

ADMA Biologics's recently published income statement conveys disappointing growth, particularly with respect to Revenue Efficiency and Return Factors metrics. ADMA Biologics management did an underwhelming job managing revenue efficiency this past period. ADMA Biologics's revenue efficiency is 94.0 according to the metrics in the current filing, which represents a 16.1% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. Its revenue efficiency, therefore, received a grade of 43. Also, ADMA Biologics's reported return on equity (ROE) ratio was -65.4, representing a change of -4.7%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. The company's return factor metrics return on equity and return on assets are even more concerning when compared to their peers. Therefore, their return factors component earned a score of 62. That said, one metric, EBITDA, stood out as strongly positive. ADMA Biologics's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as -49.9, which represents a 1.6% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. The company is headed in the right direction regarding EBITDA, exhibiting efficient capital controls and strong overall financial performance. Therefore, its EBITDA component earned a score of 65. Because of these weaknesses, their income statement received an overall score of 57.

Parameter Value Change Score
EBITDA -49.9 1.6% 65
Total Revenues 94.0 16.1% 43
Return on Equity -65.4 -4.7% 62
* All values are TTM

The below chart describes ADMA Biologics's performance as reflected on its income statement with respect to its peers. While ADMA Biologics received a income statement score of 57 , the average of its peers stands on 67.0.

  •  ADMA
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 7 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 8 1
Veracyte, Inc. 1.4B 45 63 57 55 9 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 10 1
CareDx, Inc 1.2B 61 44 82 50 11 1
MannKind Corporation 957.2M 95 48 56 61 12 1
Merus N.V. 941.6M 48 60 59 54 13 1
Amarin Corporation plc 734.5M 95 44 82 63 14 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 15 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 16 1
Radius Health, Inc. 499.8M 94 71 68 82 17 1
Affimed N.V. 415.0M 95 49 75 66 18 1
AC Immune SA 299.8M 83 61 65 70 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Overall, ADMA Biologics's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. ADMA Biologics is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.3, representing a 3.4% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. Therefore, its asset turnover movement earned a score of 85. Also, ADMA Biologics did a great job related to free cash flow this period, which stood at -0.7, representing a 17.4% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. Consequently, their free cash flow movement received a grade of 77. On the other hand, Net Cash Flow, jumped out as looking problematic. ADMA Biologics's produced underwhelming cash flow numbers in this filing. Net cash flow was reported as 7.5, which is a 256.0% change from the last report. ADMA Biologics's net cash flow metrics are especially disappointing relative to their peers. Its net cash flow, therefore, received a grade of 62. Therefore, their cash flow earned a grade of 71.

Parameter Value Change Score
Net Cashflow 7.5 256.0% 62
Capital Expenditure -13.8 -2.0% 74
Asset Turnover 0.3 3.4% 85
Free Cashflow -0.7 17.4% 77
* All values are TTM

The below chart describes ADMA Biologics's performance as reflected on its cash flow with respect to its peers. While ADMA Biologics received a cash flow score of 71, the average of its peers stands on 70.0.

  •  ADMA
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 7 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 8 1
Veracyte, Inc. 1.4B 90 95 46 46 82 9 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 10 1
CareDx, Inc 1.2B 98 84 40 50 86 11 1
MannKind Corporation 957.2M 77 56 43 37 66 12 1
Merus N.V. 941.6M 70 71 74 53 71 13 1
Amarin Corporation plc 734.5M 52 40 74 55 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 15 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 16 1
Radius Health, Inc. 499.8M 64 40 37 56 57 17 1
Affimed N.V. 415.0M 72 57 95 43 74 18 1
AC Immune SA 299.8M 66 77 79 63 68 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.